Art. -Nr.: HY-N0605

Ginsenoside Rh2

(Synonyms: 20(S)-Ginsenoside Rh2; 20(S)-Rh2)

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Ginsenoside Rh2 (20(S)-Ginsenoside Rh2) induces the activation of caspase-8 and caspase-9. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.28%
CAS. Nr.: 78214-33-2
Formel: C₃₆H₆₂O₈
Molecular Weight:622.87

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ginsenoside Rh2 Chemical Structure

CAS. Nr.: 78214-33-2

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Ginsenoside Rh2 (20(S)-Ginsenoside Rh2) induces the activation of caspase-8 and caspase-9. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner.

IC₅₀ & Target^[1]

Caspase-8

Caspase-9

Apoptosis

Alle Caspase Isoform-spezifische Produkte anzeigen :

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	28.5 mg/L Compound: Rh2	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 32702586]
B16	IC₅₀	4.1 μg/mL Compound: Rh2	Growth inhibition of mouse B16 cells Growth inhibition of mouse B16 cells	[PMID: 32702586]
B16-F10	IC₅₀	35.6 μM Compound: Rh2	Induction of cell death in mouse B16-F10 cells Induction of cell death in mouse B16-F10 cells	[PMID: 32702586]
DU-145	IC₅₀	38 μM Compound: Rh2	Antiproliferative activity against human DU-145 cells incubated for 3 days Antiproliferative activity against human DU-145 cells incubated for 3 days	[PMID: 32702586]
HCT-116	IC₅₀	19.6 μM Compound: Rh2	Cytotoxicity against human HCT-116 assessed as reduction in cell viability by MTT assay Cytotoxicity against human HCT-116 assessed as reduction in cell viability by MTT assay	[PMID: 32702586]
HCT-116	IC₅₀	35 μM Compound: Rh2	Induction of cell death in human HCT-116 cells incubated for 48 hrs by trypan blue staining based analysis Induction of cell death in human HCT-116 cells incubated for 48 hrs by trypan blue staining based analysis	[PMID: 32702586]
HeLa	IC₅₀	2.52 μg/mL Compound: Rh2	Induction of apoptosis in human HeLa cells incubated for 2 hrs by fluorescence microscopic analysis Induction of apoptosis in human HeLa cells incubated for 2 hrs by fluorescence microscopic analysis	[PMID: 32702586]
HepG2	IC₅₀	1.648 μg/mL Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 72 hrs Induction of apoptosis in human HepG2 cells incubated for 72 hrs	[PMID: 32702586]
HepG2	IC₅₀	100 μM Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 48 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 cells incubated for 48 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HepG2	IC₅₀	129.2 μM Compound: Rh2	Induction of apoptosis in human HepG2 beta-catenin cells incubated for 48 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 beta-catenin cells incubated for 48 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HepG2	IC₅₀	42.12 μM Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 24 hrs Induction of apoptosis in human HepG2 cells incubated for 24 hrs	[PMID: 32702586]
HepG2	IC₅₀	58.12 μM Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 72 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 cells incubated for 72 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HepG2	IC₅₀	83.33 μM Compound: Rh2	Induction of apoptosis in human HepG2 beta-catenin cells incubated for 72 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 beta-catenin cells incubated for 72 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HL-60	IC₅₀	25 μM Compound: Rh2	Induction of apoptosis in human HL-60 cells Induction of apoptosis in human HL-60 cells	[PMID: 32702586]
HL-60	IC₅₀	25.59 μM Compound: Rh2	Induction of apoptosis in human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of apoptosis in human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 32702586]
HL-60	IC₅₀	38 μM Compound: Rh2	Cytotoxicity against human HL-60 cells measured after 24 hrs by MTT assay Cytotoxicity against human HL-60 cells measured after 24 hrs by MTT assay	[PMID: 32702586]
Huh-7	IC₅₀	39 μM Compound: Rh2	Induction of cell death in human Huh-7 cells Induction of cell death in human Huh-7 cells	[PMID: 32702586]
Jurkat	IC₅₀	35 μM Compound: Rh2	Induction of apoptosis in human Jurkat cells Induction of apoptosis in human Jurkat cells	[PMID: 32702586]
Jurkat	IC₅₀	35 μM Compound: Rh2	Inhibition of proliferation in human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Inhibition of proliferation in human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 32702586]
K562	IC₅₀	60 μM Compound: Rh2	Cytotoxicity against human K562 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human K562 cells incubated for 48 hrs by CCK-8 assay	[PMID: 32702586]
Kasumi 1	IC₅₀	60.06 μM Compound: Rh2	Induction of apoptosis in human Kasumi 1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of apoptosis in human Kasumi 1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 32702586]
KG-1	IC₅₀	60 μM Compound: Rh2	Cytotoxicity against human KG-1 alpha cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human KG-1 alpha cells incubated for 48 hrs by CCK-8 assay	[PMID: 32702586]
KG-1	IC₅₀	75 μM Compound: Rh2	Cytotoxicity against human KG-1 alpha cells Cytotoxicity against human KG-1 alpha cells	[PMID: 32702586]
LNCaP	EC₅₀	4.4 μM Compound: Rh2	Antiproliferative activity against human LNCaP cells Antiproliferative activity against human LNCaP cells	[PMID: 32702586]
LNCaP	IC₅₀	17 μM Compound: Rh2	Antiproliferative activity against human LNCaP cells incubated for 3 days Antiproliferative activity against human LNCaP cells incubated for 3 days	[PMID: 32702586]
MCF7	EC₅₀	52.53 μM Compound: Rh2	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 32702586]
MCF7	IC₅₀	50 μM Compound: Rh2	Induction of apoptosis in human MCF7 cells assessed as inhibition of cell viability Induction of apoptosis in human MCF7 cells assessed as inhibition of cell viability	[PMID: 32702586]
MDA-MB-231	EC₅₀	57.35 μM Compound: Rh2	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 32702586]
MDA-MB-231	IC₅₀	39.9 μM Compound: Rh2	Induction of cell death in human MDA-MB-231 cells Induction of cell death in human MDA-MB-231 cells	[PMID: 32702586]
MDA-MB-231	IC₅₀	50 μM Compound: Rh2	Induction of apoptosis in human MDA-MB-231 cells assessed as inhibition of cell viability Induction of apoptosis in human MDA-MB-231 cells assessed as inhibition of cell viability	[PMID: 32702586]
PC-3	EC₅₀	5.5 μM Compound: Rh2	Antiproliferative activity against human PC-3 cells Antiproliferative activity against human PC-3 cells	[PMID: 32702586]
PC-3	IC₅₀	35 μM Compound: Rh2	Antiproliferative activity against human PC-3 cells incubated for 3 days Antiproliferative activity against human PC-3 cells incubated for 3 days	[PMID: 32702586]
REH	IC₅₀	40 μM Compound: Rh2	Induction of apoptosis in human REH cells Induction of apoptosis in human REH cells	[PMID: 32702586]
SK-HEP1	IC₅₀	3.15 μg/mL Compound: Rh2	Induction of apoptosis in human SK-HEP1 cells incubated for 2 hrs by fluorescence microscopic analysis Induction of apoptosis in human SK-HEP1 cells incubated for 2 hrs by fluorescence microscopic analysis	[PMID: 32702586]
SW480	IC₅₀	35 μM Compound: Rh2	Induction of cell death in human SW480 cells incubated for 48 hrs by trypan blue staining based analysis Induction of cell death in human SW480 cells incubated for 48 hrs by trypan blue staining based analysis	[PMID: 32702586]
SW480	IC₅₀	4.06 μg/mL Compound: Rh2	Induction of apoptosis in human SW480 cells incubated for 2 hrs by fluorescence microscopic analysis Induction of apoptosis in human SW480 cells incubated for 2 hrs by fluorescence microscopic analysis	[PMID: 32702586]
THP-1	IC₅₀	15 μg/mL Compound: Rh2	Induction of apoptosis in human THP-1 cells Induction of apoptosis in human THP-1 cells	[PMID: 32702586]
U-937	IC₅₀	38 μM Compound: Rh2	Cytotoxicity against human U-937 cells measured after 24 hrs by MTT assay Cytotoxicity against human U-937 cells measured after 24 hrs by MTT assay	[PMID: 32702586]

In Vitro

Ginsenoside Rh2 induces the activation of two initiator caspases, caspase-8 and caspase-9 in human cancer cells. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner and is therefore a promising candidate for anti-tumor drug development. Ginsenoside Rh2 triggers p53-dependent Fas expression and consequent activation of caspase-8 and p53-independent caspase-9-mediated intrinsic pathway to cause cancer cell death.The cytotoxic activity of Ginsenoside Rh2 in the human tumor cell lines HeLa, SK-HEP-1, SW480, and PC-3 is assessed by MTT. The cell viability of HeLa cells is remarkably inhibited by Ginsenoside Rh2, with an IC₅₀ value of 2.52 μg/mL, whereas SK-HEP-1 and SW480 cells are less sensitive to Ginsenoside Rh2, with IC₅₀ values of 3.15 μg/mL and 4.06 μg/mL, respectively. PC-3 cells are the least vulnerable to Ginsenoside Rh2, with an IC₅₀ value of 7.85 μg/mL, 3-fold higher than HeLa cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

A total of 15 days following B16-F10 cell injection, tumor sizes from the 3 tumor bearing groups are measured. The tumor sizes in the G-L group and G-H group (G-L and G-H refer to a low or high dose of Ginsenoside Rh2 injection) are reduced compared with the tumor group. The survival analysis reveals that the Ginsenoside Rh2 treated groups survive longer than the untreated tumor group and the effect is dose-dependent^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 78214-33-2
Appearance Solid
Molecular Weight 622.87
Formel C₃₆H₆₂O₈
Color White to off-white
SMILES

C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O[C@]([C@@H]([C@@H](O)[C@@H]4O)O)([H])O[C@@H]4CO)C)(CC[C@@]2([H])C3(C)C)[C@]5([C@@]1([H])[C@]([C@@](C)(O)CC/C=C(C)/C)([H])CC5)C
Synonyms

20(S)-Ginsenoside Rh2; 20(S)-Rh2
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All RT-PCRFlow CytometryWB

Sort by:

Journal Impact Factor

Pharmacol Res

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]

2020 May;155:104751. PMID: 32151678
J Ginseng Res

Ginsenoside Rh2 reduces m6A RNA methylation in cancer via the KIF26B-SRF positive feedback loop. [Abstract]

2021 Nov;45(6):734-743. PMID: 34764728

Ginsenoside Rh2 purchased from MedChemExpress. Usage Cited in: J Ginseng Res. 2021 Nov;45(6):734-743. [Abstract]

mRNA m6A content in Ginsenoside Rh2 treated (10 or 20 nM, 24 h) cancer cell lines.

Ginsenoside Rh2 purchased from MedChemExpress. Usage Cited in: J Ginseng Res. 2021 Nov;45(6):734-743. [Abstract]

Basal expression of KIF26B protein in three selected cancer cell lines (MDA-MB-157, NMFH-1 and TT) after treatment with Ginsenoside Rh2 (20 nM, 24 h).
Viruses

Death Receptor DR5 as a Proviral Factor for Viral Entry and Replication of Coronavirus PEDV. [Abstract]

2022 Dec 6;14(12):2724. PMID: 36560727

Ginsenoside Rh2 purchased from MedChemExpress. Usage Cited in: Viruses. 2022 Dec 6;14(12):2724. [Abstract]

Apoptosis was analyzed by Annexin V-PI double-labeling flow cytometry. Vero cells were transfected with siDR5 or siNC for 24 hours, followed by sham infection or infection with PEDV at a MOI of 0.1%. 24 hours post-infection, cells were collected, double-labeled with Annexin V and PI, and analyzed by flow cytometry. As a positive control, cells were pretreated with 100 μM Ginsenoside Rh2 (an apoptosis inducer) for 1 hour.
Food Sci Biotechnol

Fermented red ginseng extract improves sarcopenia-related muscle atrophy in old mice through regulation of muscle protein metabolism. [Abstract]

2024 Sep 23;34(3):793-802. PMID: 39958181

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (80.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6055 mL

8.0274 mL

16.0547 mL

5 mM

0.3211 mL

1.6055 mL

3.2109 mL

10 mM

0.1605 mL

0.8027 mL

1.6055 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (2.01 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (2.01 mM); Suspended solution

This protocol yields a suspended solution of ≥ 1.25 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

HeLa, SK-HEP-1, SW480, and PC-3 cells are treated with Ginsenoside Rh2 (7.5 μg/mL) in serum free media for indicated time periods and then are harvested. Fifty micrograms of cell lysates are incubated with 200 nM Ac-DEVD-AFC (for caspase-3), Ac-IETD-AFC (for caspase-8), and Ac-LEHD-AFC (for caspase-9) in a reaction buffer containing 20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM DTT, 0.1% CHAPS, and 10% sucrose at 37°C for 1 h. The reaction is monitored by fluorescence emission at 535 nm and excitation at 405 nm^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

Determination of cell viability is performed by using MTT assay, which is used to calculate the growth inhibition induced by increasing concentrations of drug. Briefly, exponentially growing HeLa, SK-HEP-1, SW480, and PC-3 cells are seeded into a 96-well plate at 1×10⁴ cells/well in triplicate. After incubation for 24 h, cells are treated with increasing concentration of Ginsenoside Rh2 (1, 2.5, 5, 7.5 and 10 μg/mL) in serum free media for 48 h. At the end of treatment, 20 μL of MTT (5 mg/mL) is added to each well and incubated for an additional 4 h. The formazan grains formed by viable cells are solubilized with DMSO, and the color intensity is measured at 550 nm with an ELISA reader^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
Male C57BL6 mice (3-4 weeks old) are randomly arranged into 4 groups of 80 mice: Tumor group, G-L group, G-H group and Control group. G-L and G-H refer to a low or high dose of ginsenoside Rh2 injection. For the tumor group, G-L group and G-H group, the B16-F10 cell line is injected into the mice. These 3 groups become tumor bearing groups. For the control group, the same volume of PBS is injected instead. Ginsenoside Rh2 is injected into the left back of mice in the G-L and G-H groups. The dose for the G-H group is 0.5 mg/kg or 0.2 mg/kg for G-L group, every 2 days after day 5. PBS is injected in the tumor and control groups at the same time points.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Guo XX, et al. p53-dependent Fas expression is critical for Ginsenoside Rh2 triggered caspase-8 activation in HeLa cells. Protein Cell. 2014 Mar;5(3):224-34. [Content Brief]

[2]. Wang M, et al. Ginsenoside Rh2 enhances the antitumor immunological response of a melanoma mice model. Oncol Lett. 2017 Feb;13(2):681-685. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6055 mL	8.0274 mL	16.0547 mL	40.1368 mL
	5 mM	0.3211 mL	1.6055 mL	3.2109 mL	8.0274 mL
	10 mM	0.1605 mL	0.8027 mL	1.6055 mL	4.0137 mL
	15 mM	0.1070 mL	0.5352 mL	1.0703 mL	2.6758 mL
	20 mM	0.0803 mL	0.4014 mL	0.8027 mL	2.0068 mL
	25 mM	0.0642 mL	0.3211 mL	0.6422 mL	1.6055 mL
	30 mM	0.0535 mL	0.2676 mL	0.5352 mL	1.3379 mL
	40 mM	0.0401 mL	0.2007 mL	0.4014 mL	1.0034 mL
	50 mM	0.0321 mL	0.1605 mL	0.3211 mL	0.8027 mL
	60 mM	0.0268 mL	0.1338 mL	0.2676 mL	0.6689 mL
	80 mM	0.0201 mL	0.1003 mL	0.2007 mL	0.5017 mL

Keywords

Ginsenoside Rh2

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ginsenoside Rh2

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Glycoside Compound Library

Lipid Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Food-Sourced Compound Library

Targeted Diversity Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Ginsenoside Rh2

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ginsenoside Rh2 Related Classifications

Art. -Nr.: HY-N0605